What Can We Learn and What Do We Need to Know Amidst the Iatrogenic Outbreak of Exserohilum Rostratum Meningitis?

被引：18
|
作者：
Kontoyiannis, Dimitrios P. [1 ,2 ]
Perlin, David S. [2 ,3 ]
Roilides, Emmanuel [2 ,4 ,5 ]
Walsh, Thomas J. [2 ,5 ,6 ,7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis, Houston, TX 77030 USA
[2] Univ Med & Dent New Jersey, Exserohilum Meningitis Res Consortium, Newark, NJ USA
[3] Univ Med & Dent New Jersey, Int Ctr Publ Hlth, Publ Hlth Res Inst, Newark, NJ USA
[4] Aristotle Univ Thessaloniki, Hippokrat Gen Hosp, Dept Pediat 3, GR-54006 Thessaloniki, Greece
[5] Weill Cornell Med Ctr, Transplantat Oncol Infect Dis Program, Div Infect Dis, New York, NY USA
[6] Weill Cornell Med Ctr, Dept Pediat, New York, NY USA
[7] Weill Cornell Med Ctr, Dept Microbiol & Immunol, New York, NY USA
来源：
CLINICAL INFECTIOUS DISEASES | 2013年 / 57卷 / 06期
关键词：
Exserohilum rostratum; meningoencephalitis; antifungals; risk factors; pathogenesis; AMPHOTERICIN-B; PARACOCCIDIOIDES-BRASILIENSIS; CEREBROSPINAL-FLUID; XYLOHYPHA-BANTIANA; FUNGAL-INFECTIONS; THERAPY; PHARMACOKINETICS; PHEOHYPHOMYCOSIS; ASPERGILLUS; RESISTANCE;
D O I：
10.1093/cid/cit283
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The tragedy of the ongoing epidemic of meningitis caused by Exserohilum rostratum brings into focus the epidemiology, risk factors, pathogenesis, diagnosis, and treatment of a multitude of opportunistic mold infections of the central nervous system. Herein we provide our perspective regarding the translational research objectives of this infection that are needed to make an impact on this important healthcare crisis.
引用
收藏
页码：853 / 859
页数：7
相关论文
共 50 条
  • [1] Isolated Nocturnal Hypertension: What Do We Know and What Can We Do?
    Tadic, Marijana
    Cuspidi, Cesare
    Grassi, Guido
    Mancia, Giuseppe
    INTEGRATED BLOOD PRESSURE CONTROL, 2020, 13 : 63 - 69
  • [2] Gender and glaucoma: what we know and what we need to know
    Vajaranant, Thasarat S.
    Nayak, Sushma
    Wilensky, Jacob T.
    Joslin, Charlotte E.
    CURRENT OPINION IN OPHTHALMOLOGY, 2010, 21 (02) : 91 - 99
  • [3] Nonalcoholic fatty liver disease: What do we know and what will we have to learn?
    Volkova, N. I.
    Porksheyan, M. I.
    TERAPEVTICHESKII ARKHIV, 2017, 89 (02) : 91 - 98
  • [4] Peripheral Arterial Disease - What Do We Need to know?
    Shanmugasundaram, Madhan
    Ram, Vinny K.
    Luft, Ulrich C.
    Szerlip, Molly
    Alpert, Joseph S.
    CLINICAL CARDIOLOGY, 2011, 34 (08) : 478 - 482
  • [5] Propofol and children - what we know and what we do not know
    Rigby-Jones, Ann E.
    Sneyd, J. Robert
    PEDIATRIC ANESTHESIA, 2011, 21 (03) : 247 - 254
  • [6] Physical activity and obesity: what we know and what we need to know
    Chin, S. -H.
    Kahathuduwa, C. N.
    Binks, M.
    OBESITY REVIEWS, 2016, 17 (12) : 1226 - 1244
  • [7] Black Mold Infections: What We Know and What We Need to Know
    Hussain N.
    Revankar S.G.
    Current Clinical Microbiology Reports, 2017, 4 (2) : 106 - 111
  • [8] Pharmacogenetics in older people: what we know and what we need to know
    Seripa, Davide
    Paroni, Giulia
    Urbano, Maria
    Santini, Stefano A.
    D'Onofrio, Grazia
    Pilotto, Alberto
    JOURNAL OF NEPHROLOGY, 2012, 25 : S38 - S47
  • [9] Prognosis of sickle cell disease in Africa: What do we know and what can we do?
    Ranque, Brigitte
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2024, 208 (05): : 660 - 670
  • [10] The emergence of Brucella canis as a public health threat in Europe: what we know and what we need to learn
    Djokic, Vitomir
    Freddi, Luca
    de Massis, Fabrizio
    Lahti, Elina
    van den Esker, Marielle H.
    Whatmore, Adrian
    Haughey, Anna
    Ferreira, Ana Cristina
    Garofolo, Giuliano
    Melzer, Falk
    Sacchini, Flavio
    Koets, Ad
    Wyllie, Stephen
    Fontbonne, Alain
    Girault, Guillaume
    Vicente, Acacia Ferreira
    Mcgiven, John
    Ponsart, Claire
    EMERGING MICROBES & INFECTIONS, 2023, 12 (02)
12345